Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
11.6 EUR | +3.57% |
|
-2.61% | -42.27% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.27% | 495M | - | ||
+75.69% | 12.57B | - | B- | |
+11.41% | 7.03B | C- | ||
-30.83% | 6.68B | C+ | ||
+9.11% | 5.25B | D+ | ||
-19.22% | 4.67B | B | ||
+19.81% | 4.07B | - | ||
-20.81% | 3.77B | B- | ||
-28.54% | 2.66B | C | ||
-2.35% | 1.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SIBN Stock
- 2K3 Stock
- Ratings SI-BONE, Inc.